Stemline Therapeutics, Inc. (STML) Posts Q1 Loss of 70c/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. TMUS
10. LMT

Go back to Stemline Therapeutics, Inc. (STML) Posts Q1 Loss of 70c/Share

Stemline Therapeutics (STML) PT Cut at Jefferies, Still Sees 288% Upside

May 19, 2014 8:15 AM EDT

Jefferies analyst Thomas Wei cut his price target on Stemline Therapeutics (NASDAQ: STML) to $50.00 (from $60.00) but reiterated a Buy rating as the new target still suggests 288% upside.

Wei comments, "STML has decided to revise its development program for SL-401 in acute... More

Roth Capital Keeps Stemline (STML) at 'Buy'; Still Plenty to See and Do in 2014

May 16, 2014 7:52 AM EDT

Roth Capital affirms its Buy rating and $62 target price on Stemline Therapeutics (Nasdaq: STML) following the company's Q1 results, which were reported after markets closed Thursday.

Analyst Joseph Pantginis sees 2014 being a pivotal year for Stemline, commenting, We expect the initiation of three key studies, each of which could garner accelerated approval by the FDA (two studies with SL-401 and one study with SL-701). Based on... More